TY - JOUR AU - Siegel, R. AU - Desantis, C. AU - Jemal, A. PY - 2014 DA - 2014// TI - Colorectal cancer statistics, 2014 JO - CA Cancer J Clin VL - 64 UR - https://doi.org/10.3322/caac.21220 DO - 10.3322/caac.21220 ID - Siegel2014 ER - TY - JOUR AU - Ferrara, N. AU - Kerbel, R. S. PY - 2005 DA - 2005// TI - Angiogenesis as a therapeutic target JO - Nature VL - 438 UR - https://doi.org/10.1038/nature04483 DO - 10.1038/nature04483 ID - Ferrara2005 ER - TY - JOUR AU - Kerbel, R. S. PY - 2008 DA - 2008// TI - Tumor angiogenesis JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMra0706596 DO - 10.1056/NEJMra0706596 ID - Kerbel2008 ER - TY - JOUR AU - Jain, R. K. PY - 2005 DA - 2005// TI - Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy JO - Science VL - 307 UR - https://doi.org/10.1126/science.1104819 DO - 10.1126/science.1104819 ID - Jain2005 ER - TY - JOUR AU - Bock, K. AU - Mazzone, M. AU - Carmeliet, P. PY - 2011 DA - 2011// TI - Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? JO - Nat Rev Clin Oncol VL - 8 UR - https://doi.org/10.1038/nrclinonc.2011.83 DO - 10.1038/nrclinonc.2011.83 ID - Bock2011 ER - TY - JOUR AU - Grothey, A. AU - Galanis, E. PY - 2009 DA - 2009// TI - Targeting angiogenesis: progress with anti-VEGF treatment with large molecules JO - Nat Rev Clin Oncol VL - 6 UR - https://doi.org/10.1038/nrclinonc.2009.110 DO - 10.1038/nrclinonc.2009.110 ID - Grothey2009 ER - TY - JOUR AU - Saltz, L. B. AU - Clarke, S. AU - Diaz-Rubio, E. AU - Scheithauer, W. AU - Figer, A. AU - Wong, R. PY - 2008 DA - 2008// TI - Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.9930 DO - 10.1200/JCO.2007.14.9930 ID - Saltz2008 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Stathopoulos, G. P. AU - Batziou, C. AU - Trafalis, D. AU - Koutantos, J. AU - Batzios, S. AU - Stathopoulos, J. PY - 2010 DA - 2010// TI - Treatment of colorectal cancer with and without bevacizumab: a phase III study JO - Oncology VL - 78 UR - https://doi.org/10.1159/000320520 DO - 10.1159/000320520 ID - Stathopoulos2010 ER - TY - JOUR AU - Passardi, A. AU - Nanni, O. AU - Tassinari, D. AU - Turci, D. AU - Cavanna, L. AU - Fontana, A. PY - 2015 DA - 2015// TI - Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv130 DO - 10.1093/annonc/mdv130 ID - Passardi2015 ER - TY - JOUR AU - Jain, R. K. AU - Duda, D. G. AU - Willett, C. G. AU - Sahani, D. V. AU - Zhu, A. X. AU - Loeffler, J. S. PY - 2009 DA - 2009// TI - Biomarkers of response and resistance to antiangiogenic therapy JO - Nat Rev Clin Oncol VL - 6 UR - https://doi.org/10.1038/nrclinonc.2009.63 DO - 10.1038/nrclinonc.2009.63 ID - Jain2009 ER - TY - JOUR AU - Folkman, J. PY - 1971 DA - 1971// TI - Tumor angiogenesis: therapeutic implications JO - N Engl J Med VL - 285 UR - https://doi.org/10.1056/NEJM197111182852108 DO - 10.1056/NEJM197111182852108 ID - Folkman1971 ER - TY - JOUR AU - Kerbel, R. S. PY - 2006 DA - 2006// TI - Antiangiogenic therapy: a universal chemosensitization strategy for cancer? JO - Science VL - 312 UR - https://doi.org/10.1126/science.1125950 DO - 10.1126/science.1125950 ID - Kerbel2006 ER - TY - JOUR AU - Winkler, F. AU - Kozin, S. V. AU - Tong, R. T. AU - Chae, S. S. AU - Booth, M. F. AU - Garkavtsev, I. PY - 2004 DA - 2004// TI - Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases JO - Cancer Cell VL - 6 ID - Winkler2004 ER - TY - JOUR AU - Tong, R. T. AU - Boucher, Y. AU - Kozin, S. V. AU - Winkler, F. AU - Hicklin, D. J. AU - Jain, R. K. PY - 2004 DA - 2004// TI - Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0074 DO - 10.1158/0008-5472.CAN-04-0074 ID - Tong2004 ER - TY - JOUR AU - Dings, R. P. AU - Loren, M. AU - Heun, H. AU - McNiel, E. AU - Griffioen, A. W. AU - Mayo, K. H. PY - 2007 DA - 2007// TI - Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-2441 DO - 10.1158/1078-0432.CCR-06-2441 ID - Dings2007 ER - TY - JOUR AU - Dickson, P. V. AU - Hamner, J. B. AU - Sims, T. L. AU - Fraga, C. H. AU - Ng, C. Y. AU - Rajasekeran, S. PY - 2007 DA - 2007// TI - Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0278 DO - 10.1158/1078-0432.CCR-07-0278 ID - Dickson2007 ER - TY - JOUR AU - Avallone, A. AU - Pecori, B. AU - Bianco, F. AU - Aloj, L. AU - Tatangelo, F. AU - Romano, C. PY - 2015 DA - 2015// TI - Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial JO - Oncotarget VL - 6 ID - Avallone2015 ER - TY - JOUR AU - Zhang, D. AU - Hedlund, E. M. AU - Lim, S. AU - Chen, F. AU - Zhang, Y. AU - Sun, B. PY - 2011 DA - 2011// TI - Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1016220108 DO - 10.1073/pnas.1016220108 ID - Zhang2011 ER - TY - JOUR AU - Shaked, Y. AU - Henke, E. AU - Roodhart, J. M. AU - Mancuso, P. AU - Langenberg, M. H. AU - Colleoni, M. PY - 2008 DA - 2008// TI - Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents JO - Cancer Cell VL - 14 UR - https://doi.org/10.1016/j.ccr.2008.08.001 DO - 10.1016/j.ccr.2008.08.001 ID - Shaked2008 ER - TY - JOUR AU - Bertolini, F. AU - Shaked, Y. AU - Mancuso, P. AU - Kerbel, R. S. PY - 2006 DA - 2006// TI - The multifaceted circulating endothelial cell in cancer: towards marker and target identification JO - Nat Rev Cancer VL - 6 UR - https://doi.org/10.1038/nrc1971 DO - 10.1038/nrc1971 ID - Bertolini2006 ER - TY - JOUR AU - Asahara, T. AU - Murohara, T. AU - Sullivan, A. AU - Silver, M. AU - Zee, R. AU - Li, T. PY - 1997 DA - 1997// TI - Isolation of putative progenitor endothelial cells for angiogenesis JO - Science VL - 275 UR - https://doi.org/10.1126/science.275.5302.964 DO - 10.1126/science.275.5302.964 ID - Asahara1997 ER - TY - JOUR AU - Mancuso, P. AU - Colleoni, M. AU - Calleri, A. AU - Orlando, L. AU - Maisonneuve, P. AU - Pruneri, G. PY - 2006 DA - 2006// TI - Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2005-11-4570 DO - 10.1182/blood-2005-11-4570 ID - Mancuso2006 ER - TY - JOUR AU - Furstenberger, G. AU - Moos, R. AU - Lucas, R. AU - Thurlimann, B. AU - Senn, H. J. AU - Hamacher, J. PY - 2006 DA - 2006// TI - Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer JO - Br J Cancer VL - 94 UR - https://doi.org/10.1038/sj.bjc.6602952 DO - 10.1038/sj.bjc.6602952 ID - Furstenberger2006 ER - TY - JOUR AU - Shaked, Y. AU - Kerbel, R. S. PY - 2007 DA - 2007// TI - Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-07-0905 DO - 10.1158/0008-5472.CAN-07-0905 ID - Shaked2007 ER - TY - JOUR AU - Willett, C. G. AU - Boucher, Y. AU - Tomaso, E. AU - Duda, D. G. AU - Munn, L. L. AU - Tong, R. T. PY - 2004 DA - 2004// TI - Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer JO - Nat Med VL - 10 UR - https://doi.org/10.1038/nm988 DO - 10.1038/nm988 ID - Willett2004 ER - TY - JOUR AU - Willett, C. G. AU - Duda, D. G. AU - Tomaso, E. AU - Boucher, Y. AU - Ancukiewicz, M. AU - Sahani, D. V. PY - 2009 DA - 2009// TI - Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.1771 DO - 10.1200/JCO.2008.21.1771 ID - Willett2009 ER - TY - JOUR AU - Alishekevitz, D. AU - Bril, R. AU - Loven, D. AU - Miller, V. AU - Voloshin, T. AU - Gingis-Velistki, S. PY - 2014 DA - 2014// TI - Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing JO - Mol Cancer Ther VL - 13 UR - https://doi.org/10.1158/1535-7163.MCT-13-0356 DO - 10.1158/1535-7163.MCT-13-0356 ID - Alishekevitz2014 ER - TY - CHAP AU - Avallone, A. AU - Gennaro, E. AU - Delrio, P. AU - Aloj, L. AU - Tatangelo, F. AU - Pecori, B. PY - 2012 DA - 2012// TI - Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers BT - 103rd annual meeting of the American Association for Cancer Research: 2012; Chicago, IL ID - Avallone2012 ER - TY - STD TI - Lanuti P, Rotta G, Almici C, Avvisati G, Budillon A, Doretto P et al. Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood. Cytometry A. 2015. doi:10.1002/cyto.a.22730. ID - ref30 ER - TY - JOUR AU - Xu, L. AU - Duda, D. G. AU - Tomaso, E. AU - Ancukiewicz, M. AU - Chung, D. C. AU - Lauwers, G. Y. PY - 2009 DA - 2009// TI - Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-09-2099 DO - 10.1158/0008-5472.CAN-09-2099 ID - Xu2009 ER - TY - JOUR AU - Ebos, J. M. AU - Lee, C. R. AU - Christensen, J. G. AU - Mutsaers, A. J. AU - Kerbel, R. S. PY - 2007 DA - 2007// TI - Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0708148104 DO - 10.1073/pnas.0708148104 ID - Ebos2007 ER - TY - JOUR AU - Schneider, B. P. AU - Wang, M. AU - Radovich, M. AU - Sledge, G. W. AU - Badve, S. AU - Thor, A. PY - 2008 DA - 2008// TI - Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.16.1612 DO - 10.1200/JCO.2008.16.1612 ID - Schneider2008 ER - TY - JOUR AU - Schneider, B. P. AU - Radovich, M. AU - Miller, K. D. PY - 2009 DA - 2009// TI - The role of vascular endothelial growth factor genetic variability in cancer JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-2576 DO - 10.1158/1078-0432.CCR-08-2576 ID - Schneider2009 ER - TY - JOUR AU - Loupakis, F. AU - Cremolini, C. AU - Fioravanti, A. AU - Orlandi, P. AU - Salvatore, L. AU - Masi, G. PY - 2011 DA - 2011// TI - Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer JO - Br J Cancer VL - 104 UR - https://doi.org/10.1038/bjc.2011.85 DO - 10.1038/bjc.2011.85 ID - Loupakis2011 ER - TY - JOUR AU - Siravegna, G. AU - Bardelli, A. PY - 2014 DA - 2014// TI - Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance JO - Genome Biol VL - 15 UR - https://doi.org/10.1186/s13059-014-0449-4 DO - 10.1186/s13059-014-0449-4 ID - Siravegna2014 ER - TY - JOUR AU - Luo, X. AU - Burwinkel, B. AU - Tao, S. AU - Brenner, H. PY - 2011 DA - 2011// TI - MicroRNA signatures: novel biomarker for colorectal cancer? JO - Cancer Epidemiol Biomark Prev VL - 20 UR - https://doi.org/10.1158/1055-9965.EPI-11-0035 DO - 10.1158/1055-9965.EPI-11-0035 ID - Luo2011 ER - TY - JOUR AU - Anand, S. AU - Cheresh, D. A. PY - 2011 DA - 2011// TI - MicroRNA-mediated regulation of the angiogenic switch JO - Curr Opin Hematol VL - 18 UR - https://doi.org/10.1097/MOH.0b013e328345a180 DO - 10.1097/MOH.0b013e328345a180 ID - Anand2011 ER - TY - JOUR AU - Zheng, T. AU - Wang, J. AU - Chen, X. AU - Liu, L. PY - 2010 DA - 2010// TI - Role of microRNA in anticancer drug resistance JO - Int J Cancer J Int Cancer VL - 126 UR - https://doi.org/10.1002/ijc.24782 DO - 10.1002/ijc.24782 ID - Zheng2010 ER - TY - JOUR AU - Cascini, G. L. AU - Avallone, A. AU - Delrio, P. AU - Guida, C. AU - Tatangelo, F. AU - Marone, P. PY - 2006 DA - 2006// TI - 18 F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer JO - J Nucl Med VL - 47 ID - Cascini2006 ER - TY - JOUR AU - Avallone, A. AU - Aloj, L. AU - Caraco, C. AU - Delrio, P. AU - Pecori, B. AU - Tatangelo, F. PY - 2012 DA - 2012// TI - Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome JO - Eur J Nucl Med Mol Imaging VL - 39 UR - https://doi.org/10.1007/s00259-012-2229-2 DO - 10.1007/s00259-012-2229-2 ID - Avallone2012 ER - TY - JOUR AU - Lastoria, S. AU - Piccirillo, M. C. AU - Caraco, C. AU - Nasti, G. AU - Aloj, L. AU - Arrichiello, C. PY - 2013 DA - 2013// TI - Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab JO - J Nucl Med VL - 54 UR - https://doi.org/10.2967/jnumed.113.119909 DO - 10.2967/jnumed.113.119909 ID - Lastoria2013 ER - TY - CHAP AU - Avallone, A. AU - Gennaro, E. AU - Delrio, P. AU - Aloj, L. AU - Tatangelo, F. AU - Pecori, B. PY - 2012 DA - 2012// TI - Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers BT - Pro 103rd annual meeting of the American Association for Cancer Research: 2012; Chicago, IL ID - Avallone2012 ER - TY - JOUR AU - Ferracin, M. AU - Lupini, L. AU - Salamon, I. AU - Saccenti, E. AU - Zanzi, M. V. AU - Rocchi, A. PY - 2015 DA - 2015// TI - Absolute quantification of cell-free microRNAs in cancer patients JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.3859 DO - 10.18632/oncotarget.3859 ID - Ferracin2015 ER - TY - JOUR AU - Siravegna, G. AU - Mussolin, B. AU - Buscarino, M. AU - Corti, G. AU - Cassingena, A. AU - Crisafulli, G. PY - 2015 DA - 2015// TI - Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3870 DO - 10.1038/nm.3870 ID - Siravegna2015 ER - TY - JOUR AU - Aaronson, N. K. AU - Ahmedzai, S. AU - Bergman, B. AU - Bullinger, M. AU - Cull, A. AU - Duez, N. J. PY - 1993 DA - 1993// TI - The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology JO - J Natl Cancer Inst VL - 85 UR - https://doi.org/10.1093/jnci/85.5.365 DO - 10.1093/jnci/85.5.365 ID - Aaronson1993 ER -